Exact Mass: 535.3046056000001
Exact Mass Matches: 535.3046056000001
Found 207 metabolites which its exact mass value is equals to given mass value 535.3046056000001
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
(4Z,7Z,10S,11E)-10-Hydroperoxy-12-[(1R,4S,5S,6R)-6-[(2Z)-pent-2-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]dodeca-4,7,11-trienoylcarnitine
(4Z,7Z,10S,11E)-10-Hydroperoxy-12-[(1R,4S,5S,6R)-6-[(2Z)-pent-2-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]dodeca-4,7,11-trienoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10S,11E)-10-hydroperoxy-12-[(1R,4S,5S,6R)-6-[(2Z)-pent-2-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]dodeca-4,7,11-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10S,11E)-10-Hydroperoxy-12-[(1R,4S,5S,6R)-6-[(2Z)-pent-2-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]dodeca-4,7,11-trienoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10S,11E)-10-Hydroperoxy-12-[(1R,4S,5S,6R)-6-[(2Z)-pent-2-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]dodeca-4,7,11-trienoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z,11Z)-3-Hydroperoxytetradeca-1,5,8,11-tetraen-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]propanoylcarnitine
3-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z,11Z)-3-hydroperoxytetradeca-1,5,8,11-tetraen-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]propanoylcarnitine is an acylcarnitine. More specifically, it is an 3-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z,11Z)-3-hydroperoxytetradeca-1,5,8,11-tetraen-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]propanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z,11Z)-3-hydroperoxytetradeca-1,5,8,11-tetraen-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]propanoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine 3-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z,11Z)-3-hydroperoxytetradeca-1,5,8,11-tetraen-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]propanoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4Z)-6-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z)-3-Hydroperoxyundeca-1,5,8-trien-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hex-4-enoylcarnitine
(4Z)-6-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z)-3-hydroperoxyundeca-1,5,8-trien-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hex-4-enoylcarnitine is an acylcarnitine. More specifically, it is an (4Z)-6-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z)-3-hydroperoxyundeca-1,5,8-trien-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hex-4-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z)-6-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z)-3-hydroperoxyundeca-1,5,8-trien-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hex-4-enoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z)-6-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z)-3-hydroperoxyundeca-1,5,8-trien-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hex-4-enoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Lys Phe Asn Lys
Glu Phe Ile Lys
Glu Phe Lys Ile
Glu Phe Lys Leu
Glu Phe Leu Lys
Glu Ile Phe Lys
Glu Ile Lys Phe
Glu Lys Phe Ile
Glu Lys Phe Leu
Glu Lys Ile Phe
Glu Lys Leu Phe
Glu Leu Phe Lys
Glu Leu Lys Phe
Phe Glu Ile Lys
Phe Glu Lys Ile
Phe Glu Lys Leu
Phe Glu Leu Lys
Phe Ile Glu Lys
Phe Ile Lys Glu
Phe Ile Arg Thr
Phe Ile Thr Arg
Phe Lys Glu Ile
Phe Lys Glu Leu
Phe Lys Ile Glu
Phe Lys Lys Asn
Phe Lys Leu Glu
Phe Lys Asn Lys
Phe Leu Glu Lys
Phe Leu Lys Glu
Phe Leu Arg Thr
Phe Leu Thr Arg
Phe Asn Lys Lys
Phe Arg Ile Thr
Phe Arg Leu Thr
Phe Arg Thr Ile
Phe Arg Thr Leu
Phe Thr Ile Arg
Phe Thr Leu Arg
Phe Thr Arg Ile
Phe Thr Arg Leu
Ile Glu Phe Lys
Ile Glu Lys Phe
Ile Phe Glu Lys
Ile Phe Lys Glu
Ile Phe Arg Thr
Ile Phe Thr Arg
Ile Ile Gln Tyr
Ile Ile Tyr Gln
Ile Lys Glu Phe
Ile Lys Phe Glu
Ile Leu Gln Tyr
Ile Leu Tyr Gln
Ile Gln Ile Tyr
Ile Gln Leu Tyr
Ile Gln Tyr Ile
Ile Gln Tyr Leu
Ile Arg Phe Thr
Ile Arg Thr Phe
Ile Thr Phe Arg
Ile Thr Arg Phe
Ile Tyr Ile Gln
Ile Tyr Leu Gln
Ile Tyr Gln Ile
Ile Tyr Gln Leu
Lys Glu Phe Ile
Lys Glu Phe Leu
Lys Glu Ile Phe
Lys Glu Leu Phe
Lys Phe Glu Ile
Lys Phe Glu Leu
Lys Phe Ile Glu
Lys Phe Lys Asn
Lys Phe Leu Glu
Lys Ile Glu Phe
Lys Ile Phe Glu
Lys Lys Phe Asn
Lys Lys Asn Phe
Lys Leu Glu Phe
Lys Leu Phe Glu
Lys Asn Phe Lys
Lys Asn Lys Phe
Leu Glu Phe Lys
Leu Glu Lys Phe
Leu Phe Glu Lys
Leu Phe Lys Glu
Leu Phe Arg Thr
Leu Phe Thr Arg
Leu Ile Gln Tyr
Leu Ile Tyr Gln
Leu Lys Glu Phe
Leu Lys Phe Glu
Leu Leu Gln Tyr
Leu Leu Tyr Gln
Leu Gln Ile Tyr
Leu Gln Leu Tyr
Leu Gln Tyr Ile
Leu Gln Tyr Leu
Leu Arg Phe Thr
Leu Arg Thr Phe
Leu Thr Phe Arg
Leu Thr Arg Phe
Leu Tyr Ile Gln
Leu Tyr Leu Gln
Leu Tyr Gln Ile
Leu Tyr Gln Leu
Asn Phe Lys Lys
Asn Lys Phe Lys
Asn Lys Lys Phe
Gln Ile Ile Tyr
Gln Ile Leu Tyr
Gln Ile Tyr Ile
Gln Ile Tyr Leu
Gln Leu Ile Tyr
Gln Leu Leu Tyr
Gln Leu Tyr Ile
Gln Leu Tyr Leu
Gln Tyr Ile Ile
Gln Tyr Ile Leu
Gln Tyr Leu Ile
Gln Tyr Leu Leu
Arg Phe Ile Thr
Arg Phe Leu Thr
Arg Phe Thr Ile
Arg Phe Thr Leu
Arg Ile Phe Thr
Arg Ile Thr Phe
Arg Leu Phe Thr
Arg Leu Thr Phe
Arg Thr Phe Ile
Arg Thr Phe Leu
Arg Thr Ile Phe
Arg Thr Leu Phe
Arg Val Val Tyr
Arg Val Tyr Val
Arg Tyr Val Val
Thr Phe Ile Arg
Thr Phe Leu Arg
Thr Phe Arg Ile
Thr Phe Arg Leu
Thr Ile Phe Arg
Thr Ile Arg Phe
Thr Leu Phe Arg
Thr Leu Arg Phe
Thr Arg Phe Ile
Thr Arg Phe Leu
Thr Arg Ile Phe
Thr Arg Leu Phe
Val Arg Val Tyr
Val Arg Tyr Val
Val Val Arg Tyr
Val Val Tyr Arg
Val Tyr Arg Val
Val Tyr Val Arg
Tyr Ile Ile Gln
Tyr Ile Leu Gln
Tyr Ile Gln Ile
Tyr Ile Gln Leu
Tyr Leu Ile Gln
Tyr Leu Leu Gln
Tyr Leu Gln Ile
Tyr Leu Gln Leu
Tyr Gln Ile Ile
Tyr Gln Ile Leu
Tyr Gln Leu Ile
Tyr Gln Leu Leu
Tyr Arg Val Val
Tyr Val Arg Val
Tyr Val Val Arg
(4Z,7Z,10S,11E)-10-Hydroperoxy-12-[(1R,4S,5S,6R)-6-[(2Z)-pent-2-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]dodeca-4,7,11-trienoylcarnitine
3-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z,11Z)-3-Hydroperoxytetradeca-1,5,8,11-tetraen-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]propanoylcarnitine
(4Z)-6-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z)-3-Hydroperoxyundeca-1,5,8-trien-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hex-4-enoylcarnitine
2-methylpropyl N-[[(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
C31H41N3O5 (535.3046056000001)
2-methylpropyl N-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
C31H41N3O5 (535.3046056000001)
2-methylpropyl N-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
C31H41N3O5 (535.3046056000001)
2-methylpropyl N-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
C31H41N3O5 (535.3046056000001)
2-methylpropyl N-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
C31H41N3O5 (535.3046056000001)
N-[(4R,7S,8S)-5-benzoyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
C31H41N3O5 (535.3046056000001)
N-[(4R,7R,8S)-5-benzoyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
C31H41N3O5 (535.3046056000001)
N-[(4S,7R,8S)-5-benzoyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
C31H41N3O5 (535.3046056000001)
N-[(4R,7R,8R)-5-benzoyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
C31H41N3O5 (535.3046056000001)
N-[(4S,7S,8R)-5-benzoyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
C31H41N3O5 (535.3046056000001)
N-[(4S,7R,8R)-5-benzoyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
C31H41N3O5 (535.3046056000001)
N-[(4R,7S,8R)-5-benzoyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
C31H41N3O5 (535.3046056000001)
2-methylpropyl N-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
C31H41N3O5 (535.3046056000001)
2-methylpropyl N-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
C31H41N3O5 (535.3046056000001)